Design, manufacturing and marketing of long term implantable medical devices dedicated to bone reconstruction for applications in orthopedic, spinal, dental and skull-maxillo-facial surgeries.The company's main aim is to conceive bioresorbable implants helping surgeons to improve patients' welfare.
Missing: Noraker's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Noraker's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Noraker
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Noraker is included in 1 Expert Collection, including Dental Health.
Companies delivering dental care products and services. Excludes practice networks.
Latest Noraker News
May 5, 2022
Disclosures: Boivin reports receiving research grants paid to his institution from Amgen, Biom’up, Hoffmann-La Roche, Eli Lilly, MSD, NIH, Noraker, Procter & Gamble, and Servier; and serving as a consultant and receiving travel grants for Amgen, MSD and Servier. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact email@example.com . Back to Healio Postmenopausal women assigned denosumab have increases in mineral to matrix ratio at the cortical and cancellous bone at 2 to 3 years, but changes were not observed beyond 5 years, according to study findings. In an analysis of data from the FREEDOM trial, denosumab therapy (Prolia, Amgen) was associated with lower mineral carbonation and a higher mineral to matrix ratio, mineral maturity and crystallinity at 2 to 3 years compared with placebo, with improvements continuing up to 5 years. However, bone mineral metrics were mostly unchanged at 10 years compared with 5 years for adults using denosumab. Source: Adobe Stock “Short- and long-term data on the effects of denosumab on matrix mineralization are of particular interest considering denosumab’s rapid and strong antiresorptive effects throughout the skeleton, including in the cancellous and cortical compartments,” Georges Boivin, PhD, emeritus director of research in the National Institute of Health and Medical Research at the University of Lyon in France, and colleagues wrote in a study published in the Journal of Bone and Mineral Research. “The FREEDOM trial and its extension provide a unique opportunity to assess the degree to which human bone matrix can have higher degree of mineralization and lower mineralization heterogeneity as a result of denosumab treatment. Furthermore, it allows one to assess the contribution of bone quality to the clinical outcomes.” Researchers collected bone matrix quality data from the FREEDOM and FREEDOM extension trials, in which postmenopausal women aged 60 to 90 years were randomly assigned to 60 mg denosumab or placebo every 6 months for 3 years. The extension trial followed up with participants at 5 and 10 years. The analysis included 42 participants from FREEDOM receiving denosumab and 30 from the placebo group. There were 28 participants from the FREEDOM extension 5-year follow-up included in the analysis and 21 from the 10-year follow-up. In the FREEDOM trial analysis, mineral to matrix bone ratio at both the cortical and cancellous compartments was higher in the denosumab group compared with placebo. Microhardness was higher in those assigned denosumab compared with placebo in the cortical bone only. Women in the 5-year follow-up group had a higher mineral to matrix ratio in both the cortical and cancellous bone at 5 years compared with 2 to 3 years. The mineral to matrix ratio in both compartments was unchanged at 10 years compared with 5 years. Mineral maturity and crystallinity were also higher at 5 years compared with 2 to 3 years, with no mineral maturity and crystallinity changes observed at 10 years, except for mineral maturity in the cancellous bone, which was higher at 10 years compared with 5 years, the researchers reported. Mineral carbonation was lower in both the cortical and cancellous bone at 5 years compared with 2 to 3 years, with no further changes at 10 years. Collagen maturity was higher in the cancellous bone at 5 years, with no further difference at 10 years. Microhardness was lower at 5 years compared with 2 to 3 years in both the cortical and cancellous bone, but no further changes were observed at 10 years, according to the study. “These data support a transition of mineral to more mature crystals and the completeness of secondary mineralization within 5 years of denosumab treatment,” the researchers wrote. “The lower microhardness at years 5 and 10 is likely the result of maturation of the organic matrix in a persistently low state of bone remodeling over 5 and 10 years.” Read more about
Noraker Web Traffic
Noraker Frequently Asked Questions (FAQ)
When was Noraker founded?
Noraker was founded in 2005.
What is Noraker's latest funding round?
Noraker's latest funding round is Incubator/Accelerator.
How much did Noraker raise?
Noraker raised a total of $30K.
Who are the investors of Noraker?
Investors of Noraker include EIT Health, EIC Accelerator and Rhone-Alpes Creation.
Who are Noraker's competitors?
Competitors of Noraker include Freedom Innovations, Cagenix, Microfabrica, Expanding Orthopedics, BioMedical Enterprises, Doctors Research Group, Tornier, Anteis, Pioneer Surgical Technology, Onset Medical and 12 more.
Compare Noraker to Competitors
Biorthex is an orthopedic device manufacturer that develops manufactures and markets innovative spinal interbody fusion devices and instruments for the treatment of degenerative conditions of the human spine
OrthAlign provides orthopedic surgeons with user-friendly and cost-effect technology for precise alignment.
Control Medical Technology designs, develops, and markets medical devices to help physicians, nurses, technicians, and other caregivers improve patient care. Its FDA-approved ASPIRE systems are used to remove fluids, tumors, bone, bone marrow, endometrial fluids, blood clots, tissue, and other pathology, targeting unmet clinical needs in oncology, orthopedics, spine, pain management and cardiovascular medicine.
Orthonicsis a company created through Georgia Tech's Venturlab program. Orthonics is developing biomaterials for orthopaedic tissue engineering applications. The company's core technology relates to biomaterials that permit in-growth and adhesion of bone and cartilage tissues. Initial applications will be spinal disc replacement and as aspinal disc annulus patch.
Developing, manufacturing, selling and exporting transcutaneousndevices which will put physiologically active substances intonsubcutaneous tissue applying the theory of electrophoresis. Developing, manufacturing, selling, exporting and importing cosmetic devices, health enhancement devices and medical devices. nnDeveloping, manufacturing, selling, exporting and importing cosmetics. All businesses that are incidental or related to the businesses stated nin the preceding items.
Doctors Research Group focuses on producing and marketing medical products. Currently, they are focusing on the development of a new type of bone cement or bone glue called Kryptonite.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.